BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26176568)

  • 1. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
    Bitar RA
    Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
    Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
    Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
    de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
    Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
    Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
    Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
    Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
    Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
    Wang XJ; Goh DYT; Dorajoo SR; Chan A
    Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
    Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
    J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
    Klastersky J; Paesmans M; Rubenstein EB; Boyer M; Elting L; Feld R; Gallagher J; Herrstedt J; Rapoport B; Rolston K; Talcott J
    J Clin Oncol; 2000 Aug; 18(16):3038-51. PubMed ID: 10944139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of febrile neutropenia in solid organ malignancies following chemotherapy.
    Lakshmaiah KC; Abhayakumar SM; Shetty R; Loknath D; Jayashree RS; Govindbabu K
    J Cancer Res Ther; 2014; 10(3):540-3. PubMed ID: 25313735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
    Paesmans M; Klastersky J; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Ameye L
    Support Care Cancer; 2011 Jul; 19(7):1001-8. PubMed ID: 20596732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
    Mohindra R; Mathew R; Yadav S; Aggarwal P
    Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department?
    Chen AY; Gottlieb M; Vilke GM; Coyne C
    J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.